Article
Biochemistry & Molecular Biology
Yuh-Ching Gau, Tsung-Jang Yeh, Chin-Mu Hsu, Samuel Yien Hsiao, Hui-Hua Hsiao
Summary: Multiple myeloma-related bone disease (MBD) is caused by an imbalance in the bone-remodeling process and involves various signaling pathways and molecules. Bisphosphonate and denosumab are currently the standard treatments, while novel bone-modifying therapies are being explored.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Pharmacology & Pharmacy
Mikkel Bo Brent
Summary: Animal models are crucial for studying the pathophysiology of bone loss and testing pharmaceutical interventions. The review highlights the importance of studying bone loss from perspectives other than post-menopausal osteoporosis and discusses the current landscape of pharmaceutical countermeasures.
PHARMACOLOGY & THERAPEUTICS
(2023)
Review
Biochemistry & Molecular Biology
Shiva Kumar Reddy Mukkamalla, Dhatri Malipeddi
Summary: Multiple myeloma (MM) is a neoplastic disease involving plasma cell proliferation in the bone marrow microenvironment, leading to overproduction of monoclonal proteins. The primary location of MM is the bone marrow, with disseminated involvement in most cases, causing myeloma bone disease and increasing infection risk. Abnormal bone remodeling in MM is characterized by osteolytic lesions and related events like hypercalcemia, bone pain, fractures, vertebral collapse, and spinal cord compression, which significantly impact patient quality of life and survival.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Biochemical Research Methods
Corrado Priami
Summary: Computational methods are increasingly important in elucidating biological systems, with this paper reviewing the most useful technologies in nutrient metabolism and metabolic disorders. While specific examples are not explored in detail due to space constraints, pointers to relevant papers are provided.
CURRENT OPINION IN BIOTECHNOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Diego Perez-Dones, Mario Ledesma-Terron, David G. Miguez
Summary: The study of vertebrate retina development can be approached from various perspectives, ranging from qualitative to quantitative, and focuses on spatial-temporal features, three-dimensional structure, and regulation at the systems level. Using the example of the developing zebrafish retina, the importance of image quality, processing, and algorithms in extracting quantitative data from dense three-dimensional tissues is highlighted. It is suggested that the scientific community focusing on developmental systems could greatly benefit from a detailed disclosure of tools and pipelines used for processing and analyzing images from biological samples.
Review
Biochemistry & Molecular Biology
Samantha Donsante, Biagio Palmisano, Marta Serafini, Pamela G. Robey, Alessandro Corsi, Mara Riminucci
Summary: Bone formation begins in the embryonic stage and continues throughout life, involving stages of bone modeling and growth, remodeling, and regeneration. Osteoblasts produce, assemble, and control mineralization of the bone matrix, while regulating other cell processes and metabolic activities. Osteoblasts are derived from different skeletal stem cells under the control of multiple regulators at different developmental stages.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Medicine, General & Internal
Simon Y. Graeber, Marcus A. Mall
Summary: Cystic fibrosis has become a leading candidate for transformative molecular therapy, with the breakthrough in highly effective modulator therapy in 2019 providing unprecedented clinical benefits. This paper reviews the understanding of the molecular mechanisms underlying CFTR dysfunction in cystic fibrosis, the progress in pharmacological approaches to restore CFTR function, and the potential of genetic therapies and gene editing approaches to cure cystic fibrosis.
Review
Pharmacology & Pharmacy
Bente L. Langdahl
Summary: Efficient therapies for osteoporosis treatment include anti-resorptive and bone-forming or dual-action treatments, with different benefits and suitability for different patient types. Long-term management plan with personalized approach is necessary for the chronic condition of osteoporosis.
BRITISH JOURNAL OF PHARMACOLOGY
(2021)
Article
Cell Biology
Sandra Charvatova, Benjamin Motais, Justyna Czapla, Tomasz Cichon, Ryszard Smolarczyk, Zuzana Walek, Sebastian Giebel, Roman Hajek, Juli R. Bago
Summary: We propose a novel approach for the local treatment of multiple myeloma bone disease (MBD) using a combination of natural killer cells (NKs) and mesenchymal stem cells (MSCs) within a fibrin scaffold, known as FINM. In vitro studies demonstrated that NKs within FINM exerted a robust anti-tumor activity against MM cells and suppressed osteoclast activity in a 3D model of MBD. The combination of FINM with other therapeutic agents showed a clear therapeutic synergistic effect.
Article
Endocrinology & Metabolism
Marta Diaz-delCastillo, Michael Tveden Gundesen, Christian Walther Andersen, Anne Lerberg Nielsen, Hanne Elisabeth Hojsgaard Moller, Pernille Just Vinholt, Jon Thor Asmussen, Ida Bruun Kristensen, Charlotte Guldborg Nyvold, Niels Abildgaard, Thomas Levin Andersen, Thomas Lund
Summary: Multiple myeloma is an incurable bone marrow cancer that leads to osteolytic lesions. Treatment often involves proteasome inhibitors, but their side effects and administration route limit long-term use. This study investigates the bone effects of ixazomib, a new-generation oral proteasome inhibitor, and suggests that it may promote bone formation by reducing bone resorption and promoting longer bone formation events.
JOURNAL OF BONE AND MINERAL RESEARCH
(2023)
Review
Dentistry, Oral Surgery & Medicine
V. F. Zymperdikas, M. P. Yavropoulou, E. G. Kaklamanos, M. A. Papadopoulos
Summary: This study aimed to assess the clinical effectiveness of bisphosphonate administration as a supplement to conventional dental treatment in patients free of bone-related diseases using network meta-analysis. The results showed that bisphosphonate treatment was associated with significant improvement in most clinical measurements, with alendronate demonstrating better outcomes compared to zoledronate or alendronate/risedronate. However, long-term effects require further data support.
JOURNAL OF DENTAL RESEARCH
(2021)
Article
Health Care Sciences & Services
Seung Han Baek, Dinah Foer, Katherine N. Cahill, Elliot Israel, Enrico Maiorino, Annika Rohl, Joshua A. Boyce, Scott T. Weiss
Summary: The study found that strong responders to imatinib (FEV1 increase >20%) shared multiple downregulated mitochondrial-related pathways, while weak responders (5-10% FEV1 increase) and non-responders did not have these pathways in common.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Editorial Material
Cell Biology
Christopher Lischer, Heiko Bruns
Summary: In their study, Cheng et al.1 demonstrate that NEK2 loss can alter the tumor microenvironment, leading to a reduction in tumor-associated macrophages and alleviating T cell exhaustion. This ultimately enhances the immune system's ability to fight against multiple myeloma.
CELL REPORTS MEDICINE
(2023)
Review
Immunology
Monica Roman-Trufero, Holger W. Auner, Claire M. Edwards
Summary: Multiple myeloma is an incurable cancer of plasma cells that primarily affects the bone marrow. This article discusses the major metabolic characteristics of plasma cells and myeloma cells, their roles in disease progression, and potential therapeutic applications. It also explores the complex relationship between myeloma cells and the bone marrow microenvironment.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Hematology
Eline Menu, Karin Vanderkerken
Summary: This review summarizes the role of exosomes in multiple myeloma (MM), including their involvement in osteolysis, angiogenesis, immune suppression, and drug resistance. Targeting exosome secretion could potentially block these processes. The review also discusses current treatment strategies to counter these processes and explores how exosomes can be harnessed to deliver toxic payloads. Additionally, the review provides an overview of clinical studies investigating exosome cargo as potential MM biomarkers in liquid biopsies.
Article
Biochemistry & Molecular Biology
Georgia Trakada, Despina Fotiou, Anastasios Kallianos, Foteini Theodorakakou, Magdalini Migkou, Maria Gavriatopoulou, Nikolaos Kanellias, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Evangelos Eleutherakis-Papaiakovou, Ioanna Dialoupi, Evangelos Terpos, Meletios A. Dimopoulos, Efstathios Kastritis
Summary: Pulmonary dysfunction is common and underrecognized in patients with systemic AL amyloidosis. Restrictive breathing physiology is associated with worse survival. Decreased forced vital capacity, forced expiratory volume, and carbon monoxide diffusion capacity are associated with poorer prognosis. Respiratory muscle strength is affected in most patients, and maximal expiratory pressure is an independent prognostic factor.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS
(2023)
Article
Endocrinology & Metabolism
Stavroula A. Paschou, Vangelis Karalis, Theodora Psaltopoulou, Ioanna Charitaki, Aimilia D. Sklirou, Vassiliki A. Iconomidou, Vasiliki Vasileiou, Georgia N. Kassi, Andromachi Vryonidou, Alexander Kokkinos, Nicholas Tentolouris, Erifili Hatziaggelaki, Ioannis P. Trougakos, Evangelos Terpos, Meletios Athanasios Dimopoulos
Summary: This study compares the kinetics of neutralizing antibodies after vaccination with the BNT162b2 mRNA vaccine between patients with T2DM and healthy controls. The results show that patients with T2DM exhibit a similar immunological response to the vaccine as healthy subjects.
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM
(2023)
Review
Oncology
Efstathia Liatsou, Diamantis I. I. Tsilimigras, Panagiotis Malandrakis, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos
Summary: New perspectives on the role of metastasectomy have emerged along with the advances in cancer immunotherapy. This review provides a comprehensive evidence on the current literature and ongoing trials about the combination of immunotherapy and surgical resection in metastatic cancer. Immune checkpoint inhibitors have shown promising results in various types of metastatic cancers.
EXPERT REVIEW OF ANTICANCER THERAPY
(2023)
Article
Hematology
Santhi Devasundaram, Evangelos Terpos, Margherita Rosati, Ioannis Ntanasis-Stathopoulos, Jenifer Bear, Robert Burns, Stamatia Skourti, Panagiotis Malandrakis, Ioannis P. Trougakos, Meletios-Athanasios Dimopoulos, George N. Pavlakis, Barbara K. Felber
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Medicine, Research & Experimental
Maria-Alexandra Papadimitriou, Konstantinos Soureas, Aristea-Maria Papanota, Panagiotis Tsiakanikas, Panagiotis G. G. Adamopoulos, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Maria Gavriatopoulou, Diamantis C. C. Sideris, Efstathios Kastritis, Margaritis Avgeris, Meletios-Athanasios Dimopoulos, Evangelos Terpos, Andreas Scorilas
Summary: The overexpression of miR-25 is associated with poor prognosis and disease progression in multiple myeloma patients, and it can be used as a powerful predictive tool for personalized treatment decisions.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Review
Oncology
Evangelos Terpos, Pellegrino Musto, Monika Engelhardt, Michel Delforge, Gordon Cook, Francesca Gay, Niels W. C. J. van de Donk, Ioannis Ntanasis-Stathopoulos, Annette Juul Vangsted, Christoph Driessen, Fredrik Schjesvold, Claudio Cerchione, Sonja Zweegman, Roman Hajek, Philippe Moreau, Hermann Einsele, Jesus San-Miguel, Mario Boccadoro, Meletios A. A. Dimopoulos, Pieter Sonneveld, Heinz Ludwig
Summary: In the post-pandemic COVID-19 period, patients with multiple myeloma (MM) are at increased risk for severe COVID-19 outcomes. The European Myeloma Network recommends vaccination with variant-specific booster vaccines every 6-12 months to overcome the emergence of novel strains. Evaluation of immune response after vaccination can identify vulnerable patients who may need additional boosters and preventive measures. Certain antiviral drugs are effective against specific Omicron subvariants and should be administered in MM patients with positive COVID-19 tests or symptoms.
Letter
Oncology
Despina Fotiou, Foteini Theodorakakou, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, Nikolaos Kanellias, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Asimina Papanikolaou, Charikleia Gakiopoulou, Evangelos Terpos, Meletios Athanasios Dimopoulos, Efstathios Kastritis
LEUKEMIA & LYMPHOMA
(2023)
Review
Oncology
Efstathia Liatsou, Ioannis Ntanasis-Stathopoulos, Stavros Lykos, Anastasios Ntanasis-Stathopoulos, Maria Gavriatopoulou, Theodora Psaltopoulou, Theodoros N. Sergentanis, Evangelos Terpos
Summary: This study aimed to evaluate the efficacy of COVID-19 vaccination among patients with different types of malignancies. The results showed that cancer patients had suboptimal immune responses after COVID-19 vaccination, especially those with hematological malignancies. The immune response was found to be affected by factors such as timing of vaccination in relation to active therapy, type of therapy, and type of cancer.
Letter
Oncology
Evangelos Terpos, Pellegrino Musto, Monika Engelhardt, Ioannis Ntanasis-Stathopoulos, Pieter Sonneveld, Heinz Ludwig
Article
Immunology
Maria Geropeppa, Ioanna Papadatou, Panagiotis Sarantis, Marianna Tzanoudaki, Ioannis Ntanasis-Stathopoulos, Tina Bagratuni, Evangelos Terpos, Vana Spoulou
Summary: mRNA vaccines have played an important role in controlling the SARS-CoV-2 pandemic, but the protection they provide is short-lived, requiring frequent revaccinations. The development of RBD-specific B cell memory is crucial for improving the immune response, but the effect of additional doses of mRNA vaccines on this memory pool is unclear.
Review
Medicine, General & Internal
Efstathia Liatsou, Ioanna Tatouli, Andreas Mpozikas, Maria-Markella Pavlou, Hariklia Gakiopoulou, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, Sofoklis Kontogiannis, Meletios Athanasios Dimopoulos
Summary: Tenofovir disoproxil fumarate (TDF) is a drug used to treat patients with HIV and HBV infections, but it may cause acute renal failure and Fanconi syndrome in a few cases. The risk of renal toxicity in HBV patients appears to be low, but kidney function should still be monitored.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Virology
Christina Zirou, Sentiljana Gumeni, Ioannis Bellos, Ioannis Ntanasis-Stathopoulos, Aimilia D. Sklirou, Tina Bagratuni, Eleni Korompoki, Filia Apostolakou, Ioannis Papassotiriou, Ioannis P. Trougakos, Evangelos Terpos
Summary: This study aimed to evaluate the immune response and effects of vaccination in recovered COVID-19 patients up to one year after natural infection. The results showed that severe disease was associated with higher antibody levels up to 6 months after infection, while mild disease was associated with lower antibody levels. Vaccination significantly increased antibody levels in recovered patients, regardless of disease severity.
Article
Biochemistry & Molecular Biology
Ioanna Barla, Panagiotis Efentakis, Sofia Lamprou, Maria Gavriatopoulou, Meletios-Athanasios Dimopoulos, Evangelos Terpos, Ioanna Andreadou, Nikolaos Thomaidis, Evangelos Gikas
Summary: The antineoplastic agent carfilzomib (Cfz) is used to treat multiple myeloma; however, it can cause cardiotoxicity and nephrotoxicity as common adverse effects. While the mechanisms of these side effects are well-established, there is limited research on the drug's metabolic alterations and their impacts.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Medicine, Research & Experimental
Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, Maria Gavriatopoulou, Panagiotis Malandrakis, Evangelos Eleutherakis-Papaiakovou, Vassiliki Spiliopoulou, Rodanthi-Eleni Syrigou, Foteini Theodorakakou, Despina Fotiou, Magdalini Migkou, Maria Roussou, Efstathios Kastritis, Meletios Athanasios Dimopoulos, Evangelos Terpos
Summary: Tixagevimab/cilgavimab (Evusheld) appears to be beneficial for high-risk immunocompromised patients with multiple myeloma in preventing COVID-19. Administration of the drug resulted in increased neutralizing-antibody levels and a low incidence of COVID-19, with no new safety concerns emerging.
